{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T21:46:10Z","timestamp":1765143970462,"version":"3.40.4"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104306"],"award-info":[{"award-number":["82104306"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2024JJ5465"],"award-info":[{"award-number":["2024JJ5465"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for the Central Universities of Central South University","doi-asserted-by":"publisher","award":["2024ZZTS0983"],"award-info":[{"award-number":["2024ZZTS0983"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Ampicillin, a \u03b2-lactam antibiotic frequently prescribed for bacterial infections, is used off-label in neonates. Blood sampling limitations in neonatal pharmacokinetic (PK) studies make dried blood spots (DBS) a promising matrix for micro-sampling. This study aims to develop a population PK (PopPK) model using a DBS-based approach to optimize ampicillin dosing in Chinese neonatal patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>DBS samples were collected at predefined intervals from neonatal patients after ampicillin dosing. A PopPK model was developed using NONMEM 7.5, followed by model-based simulations to provide dosing recommendations in virtual population. During the simulations, the predicted blood concentrations were converted to unbound plasma concentrations using a blood-to-plasma ratio of 0.56 and an unbound fraction of 0.8. The PK\/pharmacodynamic (PD) target was 100% of the time with the unbound drug plasma concentration above the MIC (%fT\u200a&amp;gt;\u200aMIC), and the risk of toxicity threshold was defined as a steady-state peak plasma concentration exceeding 140\u2005mg\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data from 53 patients with 102 DBS samples were collected, and the ranges of body weight and postmenstrual age (PMA) were 1.91\u20134.25\u2005kg and 34.3\u201341.4\u2005weeks, respectively. Ampicillin PK were characterized using a one-compartment model with first-order elimination. An allometric scaling and renal maturation model were integrated into the model to describe the developmental PK in hospitalized neonates. Simulations suggest that the optimal dosing regimen is 25\u2005mg\/kg administered intravenously every 6 h across PMA of 32\u201342 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We successfully developed a PopPK model of ampicillin using DBS sampling for Chinese neonates and proposed evidence-based dosing recommendations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf091","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:01:11Z","timestamp":1742587271000},"page":"1427-1436","source":"Crossref","is-referenced-by-count":1,"title":["Utilizing dried blood spot micro-sampling and population pharmacokinetic modelling and simulation to inform ampicillin dosing in Chinese neonates"],"prefix":"10.1093","volume":"80","author":[{"given":"Jianmei","family":"Lv","sequence":"first","affiliation":[{"name":"Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University , Changsha 410013 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rao","family":"Li","sequence":"additional","affiliation":[{"name":"The Department of Dermatology, Xiangya Hospital, Central South University , Changsha 410008 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanyao","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution, Scientific Research and lnnovation Center, Women and Children\u2019s Hospital, School of Medicine, Xiamen University , Xiamen ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Trial Institution, Scientific Research and lnnovation Center, Women and Children\u2019s Hospital, School of Medicine, Xiamen University , Xiamen ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Women and Children\u2019s Hospital, School of Medicine, Xiamen University , Xiamen ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Women and Children\u2019s Hospital, School of Medicine, Xiamen University , Xiamen ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huayan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Women and Children\u2019s Hospital, School of Medicine, Xiamen University , Xiamen ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-2676","authenticated-orcid":false,"given":"Feifan","family":"Xie","sequence":"additional","affiliation":[{"name":"Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University , Changsha 410013 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"2025050205522634100_dkaf091-B1","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s10875-015-0128-6","article-title":"An impaired inflammatory cytokine response to gram-negative LPS in human neonates is associated with the defective TLR-mediated signaling pathway","volume":"35","author":"Li","year":"2015","journal-title":"J Clin Immunol"},{"key":"2025050205522634100_dkaf091-B2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.pcl.2017.03.008","article-title":"A neonatal and perinatal infections","volume":"64","author":"Khan","year":"2017","journal-title":"Pediatr Clin North Am"},{"key":"2025050205522634100_dkaf091-B3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jmii.2021.05.004","article-title":"Antibiotic resistance in neonates in China 2012\u20132019: a multicenter study","volume":"55","author":"Tan","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"2025050205522634100_dkaf091-B4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13756-024-01440-2","article-title":"Trends in the antimicrobial susceptibility among Chinese neonates from 2012 to 2021: a multicenter study","volume":"13","author":"Yin","year":"2024","journal-title":"Antimicrob Resist Infect Control"},{"key":"2025050205522634100_dkaf091-B5","doi-asserted-by":"publisher","first-page":"608352","DOI":"10.3389\/fcimb.2021.608352","article-title":"Listeriosis cases and genetic diversity of their L. monocytogenes isolates in China, 2008\u20132019","volume":"11","author":"Lu","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"author":"US FDA","key":"2025050205522634100_dkaf091-B6"},{"key":"2025050205522634100_dkaf091-B7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/s0003-0465(16)34104-0","article-title":"Ampicillin","volume":"15","author":"Jusko","year":"1975","journal-title":"J Am Pharm Assoc"},{"key":"2025050205522634100_dkaf091-B8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.clp.2014.10.009","article-title":"New antibiotic dosing in infants","volume":"42","author":"Pineda","year":"2015","journal-title":"Clin Perinatol"},{"key":"2025050205522634100_dkaf091-B9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/phar.1916","article-title":"Population pharmacokinetics and pharmacodynamic target attainment of ampicillin in neonates with hypoxemic-ischemic encephalopathy in the setting of controlled hypothermia","volume":"37","author":"Cies","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2025050205522634100_dkaf091-B10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of beta-lactams","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2025050205522634100_dkaf091-B11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1055\/s-0040-1718880","article-title":"Ampicillin dose for early and late-onset group B streptococcal disease in neonates","volume":"39","author":"Lim","year":"2022","journal-title":"Am J Perinatol"},{"key":"2025050205522634100_dkaf091-B12","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/s41372-022-01344-2","article-title":"Ampicillin dosing in premature infants for early-onset sepsis: exposure-driven efficacy, safety, and stewardship","volume":"42","author":"Le","year":"2022","journal-title":"J Perinatol"},{"key":"2025050205522634100_dkaf091-B13","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1128\/AAC.02374-13","article-title":"Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design","volume":"58","author":"Tremoulet","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205522634100_dkaf091-B14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/INF.0000000000003061","article-title":"Ampicillin pharmacokinetics during first week of life in preterm and term neonates","volume":"40","author":"Padari","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"2025050205522634100_dkaf091-B15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/INF.0000000000002663","article-title":"Paradoxical antibiotic effect of ampicillin: use of a population pharmacokinetic model to evaluate a clinical correlate of the eagle effect in infants with bacteremia","volume":"39","author":"Ericson","year":"2020","journal-title":"Pediatr Infect Dis J"},{"volume-title":"NeoFax 2020","year":"2020","author":"Thomas","key":"2025050205522634100_dkaf091-B16"},{"volume-title":"BNF for Children 2020\u20132021","year":"2020","author":"Paediatric Formulary Committee","key":"2025050205522634100_dkaf091-B17"},{"key":"2025050205522634100_dkaf091-B18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jpeds.2016.07.011","article-title":"Electronic health records and pharmacokinetic modeling to assess the relationship between ampicillin exposure and seizure risk in neonates","volume":"178","author":"Hornik","year":"2016","journal-title":"J Pediatr"},{"key":"2025050205522634100_dkaf091-B19","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0022-3476(87)80219-6","article-title":"Ethics of drug studies in infants: how many samples are required for accurate estimation of pharmacokinetic parameters in neonates?","volume":"111","author":"Long","year":"1987","journal-title":"J Pediatr"},{"issue":"Suppl 1","key":"2025050205522634100_dkaf091-B20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00228-009-0782-9","article-title":"The role of population PK-PD modelling in paediatric clinical research","volume":"67","author":"De Cock","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"2025050205522634100_dkaf091-B21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/dta.1646","article-title":"Dried blood spots: concepts, present status, and future perspectives in bioanalysis","volume":"6","author":"Sharma","year":"2014","journal-title":"Drug Test Anal"},{"key":"2025050205522634100_dkaf091-B22","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","article-title":"Basic concepts in population modeling, simulation, and model-based drug development\u2014part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025050205522634100_dkaf091-B23","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1038\/psp.2012.4","article-title":"Basic concepts in population modeling, simulation, and model-based drug development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025050205522634100_dkaf091-B24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/antibiotics12020199","article-title":"A validated UHPLC-MS\/MS method to quantify eight antibiotics in quantitative dried blood spots in support of pharmacokinetic studies in neonates","volume":"12","author":"Liu","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2025050205522634100_dkaf091-B25","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/psp4.13115","article-title":"Covariate modeling in pharmacometrics: general points for consideration","volume":"13","author":"Sanghavi","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025050205522634100_dkaf091-B26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1126\/science.276.5309.122","article-title":"A general model for the origin of allometric scaling laws in biology","volume":"276","author":"West","year":"1997","journal-title":"Science"},{"key":"2025050205522634100_dkaf091-B27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","article-title":"Human renal function maturation: a quantitative description using weight and postmenstrual age","volume":"24","author":"Rhodin","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"2025050205522634100_dkaf091-B28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/FTD.0000000000000466","article-title":"Comparative analysis of ampicillin plasma and dried blood spot pharmacokinetics in neonates","volume":"40","author":"Le","year":"2018","journal-title":"Ther Drug Monit"},{"key":"2025050205522634100_dkaf091-B29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/jcph.6145","article-title":"Dried blood spots sampling and population pharmacokinetic modeling for dosing optimization of piperacillin in Chinese neonates","volume":"65","author":"Li","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"2025050205522634100_dkaf091-B30","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","article-title":"Therapeutic drug monitoring by dried blood spot: progress to date and future directions","volume":"53","author":"Wilhelm","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"2025050205522634100_dkaf091-B31","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.4155\/bio.13.156","article-title":"Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions","volume":"5","author":"De Kesel","year":"2013","journal-title":"Bioanalysis"},{"key":"2025050205522634100_dkaf091-B32","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/17512433.2023.2224562","article-title":"Dried blood spot sampling for therapeutic drug monitoring: challenges and opportunities","volume":"16","author":"M\u00fcller","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2025050205522634100_dkaf091-B33","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jcph.831","article-title":"Allometry is a reasonable choice in pediatric drug development","volume":"57","author":"Liu","year":"2017","journal-title":"J Clin Pharmacol"},{"author":"European Committee on Antimicrobial Susceptibility Testing","key":"2025050205522634100_dkaf091-B34"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1427\/62493204\/dkaf091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1427\/62493204\/dkaf091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:52:36Z","timestamp":1746179556000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/5\/1427\/8088204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,20]]},"published-print":{"date-parts":[[2025,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf091","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,20]]}}}